A Double-Blind, Placebo-Controlled Study Of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder.

Trial Profile

A Double-Blind, Placebo-Controlled Study Of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 01 Mar 2016 Results published in the Journal of Clinical Psychiatry
    • 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 21 Mar 2014 Top-line results have been reported in a Forest Laboratories and Gedeon Richter media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top